Onyx Biotec Limited (NSE:ONYX)
India · Delayed Price · Currency is INR 29.80
0.00 (0.00%)
At close: May 25, 2026
Onyx Biotec Revenue
In the fiscal year ending March 31, 2026, Onyx Biotec had annual revenue of 699.14M INR with 12.85% growth. Onyx Biotec had revenue of 345.85M in the half year ending September 30, 2025, with 44.76% growth.
Revenue
699.14M
Revenue Growth
+12.85%
P/S Ratio
0.77
Revenue / Employee
1.96M
Employees
357
Market Cap
540.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 699.14M | 79.63M | 12.85% |
| Mar 31, 2025 | 619.51M | 82.03M | 15.26% |
| Mar 31, 2024 | 537.49M | 142.57M | 36.10% |
| Mar 31, 2023 | 394.92M | -53.70M | -11.97% |
| Mar 31, 2022 | 448.61M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mangalam Drugs & Organics | 2.33B |
| ANG Lifesciences India | 862.13M |
| Sandu Pharmaceuticals | 699.35M |
| Source Natural Foods and Herbal Supplements | 654.13M |
| Shelter Pharma | 598.96M |
| Rajnish Wellness | 455.79M |
| Phaarmasia | 449.06M |
| Amwill Health Care | 386.31M |